Lakefront Biotherapeutics (LKFT) Long-Term Investments (2015 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Long-Term Investments for 5 consecutive years, with $54.5 million the latest figure, recorded in Q1 2026.

• Quarterly Long-Term Investments fell 5.75% year-over-year to $54.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $54.5 million (down 5.75% YoY) and the FY2025 annual result came in at $53.3 million, down 76.62% from the prior year.
• Long-Term Investments rose to $54.5 million in Q1 2026 per LKFT's latest filing, from $53.3 million in the prior quarter.
• Over the last five years, Long-Term Investments for LKFT reached as high as $227.8 million in Q4 2024 and fell as low as $15.4 million in Q4 2023.
• A 4-year average of $71.4 million and a median of $54.0 million in 2025 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2024 — Long-Term Investments jumped 1374.64% — and 2025, when it slumped 76.62%.
• Year by year, Long-Term Investments stood at $15.4 million in 2023, then soared by 1374.64% to $227.8 million in 2024, then sank by 76.62% to $53.3 million in 2025, then gained by 2.4% to $54.5 million in 2026.
• According to Business Quant data, Long-Term Investments over the past three periods registered $54.5 million, $53.3 million, and $53.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.